Recce Pharmaceuticals EU

Recce Pharmaceuticals (FSE:$R9Q) is pioneering a new class of Synthetic Anti-Infectives to combat antibiotic resistant #superbugs & emerging viral pathogens

[Recce Pharmaceuticals EU @ReccePharmaEU]

🦠🔬Recce is pioneering the development and commercialisation of a New Class of Synthetic #AntiInfectives designed to address the urgent global health threat posed by #AntibioticResistant #Superbugs and emerging viral pathogens with a unique #MechanismofAction

[Recce Pharmaceuticals Ltd @ReccePharma]

ABSSSI includes severe skin infections like cellulitis and abscesses. Resistance is rising, and current treatments are failingABSSSI includes severe skin infections like cellulitis and abscesses. Resistance is rising, and current treatments are failingABSSSI includes severe skin infections like cellulitis and abscesses. Resistance is rising, and current treatments are failingABSSSI includes severe skin infections like cellulitis and abscesses. Resistance is rising, and current treatments are failingABSSSI includes severe skin infections like cellulitis and abscesses. Resistance is rising, and current treatments are failingABSSSI includes severe skin infections like cellulitis and abscesses. Resistance is rising, and current treatments are failing.

[Recce Pharmaceuticals Ltd @ReccePharma]

Recurrent UTIs aren’t always new infections, many are relapses from bacteria hiding in biofilms. Shielded from antibiotics, they persist and drive resistance. New strategies must break through the biofilm barrierRecurrent UTIs aren’t always new infections, many are relapses from bacteria hiding in biofilms. Shielded from antibiotics, they persist and drive resistance. New strategies must break through the biofilm barrierRecurrent UTIs aren’t always new infections, many are relapses from bacteria hiding in biofilms. Shielded from antibiotics, they persist and drive resistance. New strategies must break through the biofilm barrierRecurrent UTIs aren’t always new infections, many are relapses from bacteria hiding in biofilms. Shielded from antibiotics, they persist and drive resistance. New strategies must break through the biofilm barrierRecurrent UTIs aren’t always new infections, many are relapses from bacteria hiding in biofilms. Shielded from antibiotics, they persist and drive resistance. New strategies must break through the biofilm barrier.

[Recce Pharmaceuticals Ltd @ReccePharma]

R327 was featured in the WHO 2025 antibacterial pipeline report as one of the few therapies targeting bacterial ATP.

This rare mechanism offers a new way to fight infections, especially when traditional antibiotics no longer workR327 was featured in the WHO 2025 antibacterial pipeline report as one of the few therapies targeting bacterial ATP.

This rare mechanism offers a new way to fight infections, especially when traditional antibiotics no longer workR327 was featured in the WHO 2025 antibacterial pipeline report as one of the few therapies targeting bacterial ATP.

This rare mechanism offers a new way to fight infections, especially when traditional antibiotics no longer workR327 was featured in the WHO 2025 antibacterial pipeline report as one of the few therapies targeting bacterial ATP.

This rare mechanism offers a new way to fight infections, especially when traditional antibiotics no longer workR327 was featured in the WHO 2025 antibacterial pipeline report as one of the few therapies targeting bacterial ATP.

This rare mechanism offers a new way to fight infections, especially when traditional antibiotics no longer work.

[Recce Pharmaceuticals Ltd @ReccePharma]

Recce Pharmaceuticals Managing Director and CEO James Graham joins Stockhead TV following a bumper capital raising. #ASX #health $RCE

[Proactive USA @proactive_NA]

Recce Pharmaceuticals completes shortfall placement to raise $7.4 million @ReccePharma #ASX #OTC #RCE #RECEF https://t.co/3NUOgWJQxO

[Stockhead @StockheadAU]

Developer of a new class of synthetic anti-infectives, Recce Pharmaceuticals has received firm commitments to place the full shortfall from its recent 1-for-6 pro-rata non-renounceable entitlement offer. #ASX $RCE @ReccePharma https://t.co/B5bfibaTQ7

[Recce Pharmaceuticals Ltd @ReccePharma]

#ASX Announcement - Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), is pleased to announce it has received firm commitments to place all of the shortfall shares from the recent 1- for-6 pro-rata non-renounceable entitlement offer, the results of which were announced on 16 May 2025.

Read the full ann here: https://t.co/xX0vpHebAF

[Recce Pharmaceuticals Ltd @ReccePharma]

Not all #antibiotics are created equal.
Our CSO Michele explains what makes Recce’s #AntiInfectives uniquely powerful in treating resistant #infections.

[Recce Pharmaceuticals Ltd @ReccePharma]

Learning about #handhygiene and #SafeGlove use matters.
Help raise awareness this World Hand Hygiene Day to reduce the spread of infections between healthcare workers, patients and the wider community.

Find out more: https://t.co/Kb6EHWUtre
#WHHD @ACSQHC @WHO #NHHI #infectionprevention

[Recce Pharmaceuticals Ltd @ReccePharma]

#ASX Ann - Recce Pharmaceutical (ASX:RCE, FSE:R9Q), is pleased to announce that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (@OUSAMRIID), with partnership and funding from the Defense Threat Reduction Agency.

Read the full ann here: https://t.co/37eOu505GP

[Recce Pharmaceuticals Ltd @ReccePharma]

Missed our Investor Webinar?
Catch up on the latest clinical updates, our Phase 3 outlook & capital raise strategy as we progress toward commercialisation in 2026.
🔗Watch the full recording now on our YouTube: https://t.co/7stFUuUc5R

[Recce Pharmaceuticals Ltd @ReccePharma]

#ASX Ann - Recce Pharmaceuticals (ASX:RCE, FSE:R9Q), is pleased to announce it has received Human Research Ethics Approval (HREC) approval to build upon its Phase II Clinical Trial for the treatment of Diabetic Foot Infections (#DFI) by enrolling up to 20 additional patients with DFI, to provide access to #R327G in this open-label study.

Read the full ann here: https://t.co/xX0vpHebAF

[Recce Pharmaceuticals Ltd @ReccePharma]

#ASXAnnouncement: Our latest investor presentation, "Commercialising a New Class of Synthetic Anti-Infectives," is now available! Learn more about the work that Recce's doing.

View the full presentation here: https://t.co/1qgCqGNaxI

[Recce Pharmaceuticals Ltd @ReccePharma]

Biocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trial. Read the full article here via The Australian: https://t.co/P9Xal9e6R5

[Recce Pharmaceuticals Ltd @ReccePharma]

In case you missed our webinar, don't worry! You can now view the full session on our YouTube channel.

Watch the webinar here: https://t.co/SqqzC2YXSd

[Recce Pharmaceuticals Ltd @ReccePharma]

Join Recce Pharmaceuticals for a live webinar today at 11 am AEDT as we dive into key clinical milestones and the future of our #AntiInfective programs. Hear from industry experts and get the latest insights!

Secure your spot: https://t.co/kkCW52egNL

[Recce Pharmaceuticals Ltd @ReccePharma]

#ASX Announcement - Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), is pleased to announce the receipt of a notice of allowance from the Japan Patent Office for Patent Family 4 for Recce’s Anti-infectives, expiry 2041.

Read the full ann here: https://t.co/1qgCqGNaxI

[Recce Pharmaceuticals Ltd @ReccePharma]

Reading alert: Bacteria Evolve Antimicrobial Resistance More Rapidly in Diabetes Model.
Antibiotic-resistant strains of Staphylococcus aureus flourish in a #DiabeticInfection environment.

Read the article here: https://t.co/qXqXmmYWG4

[Recce Pharmaceuticals Ltd @ReccePharma]

Recce is in @FierceBiotech! Our synthetic antibiotic R327 Gel is making headlines for its promising Phase 2 clinical trial results, offering a potential breakthrough for skin infections and #AMR.

📖 Read the full article: https://t.co/OybVCh5NmB

[Recce Pharmaceuticals Ltd @ReccePharma]

Responding to an emerging world health problem: Recce Pharmaceuticals has entered global #ClinicalTrials with a product that could be a game changer for the medical industry. @manmonthly

Read the full article on pages 48 & 49: https://t.co/9UpNWvpJAv